Patents Assigned to Kaken Pharmaceutical Company, Ltd.
  • Patent number: 7476648
    Abstract: According to the present invention, a vessel embolic material comprising a hydrogel containing a cell growth factor, which is applicable to embolic operations for various vascular disorders, excellent in high adaptability to a living body, can be easily handled, ensures the occlusion of the affected part and can maintain the occlusion for a long time, and a method of treatment using the same can be provided.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: January 13, 2009
    Assignees: Kaken Pharmaceutical Company, Ltd.
    Inventors: Yasuhiko Tabata, Susumu Miyamoto
  • Patent number: 6732738
    Abstract: There are disclosed a method to enhance sternal treatment after sternotomy with or without removal of at least one of thoracic arteries which comprises applying an agent for the treatment of sternum after sternotomy to or at around the sternum, wherein the agent comprises at least one selected from the group consisting of an angiogenetic factor, an osteogenetic factor and their analogues such as bFGF, aFGF, TGF &bgr;, VEGF, HGF, BMP, PDGF, TGF &agr;, other cytokines or gene as an effective ingredient and an agent to be used for the method; and an agent to enhance healing of or treating sternum after sternotomy comprising the same.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: May 11, 2004
    Assignees: Kaken Pharmaceutical Company, Ltd.
    Inventors: Masashi Komeda, Yasuhiko Tabata
  • Patent number: 6306893
    Abstract: An object of the invention is to develop galactose or mannose derivatives of docetaxel, etc. having improved solubility and physiological activity, to alleviate burden imposed on patients and to provide effective therapeutic drug for tumors. The present invention provides taxoid derivatives comprising any of paclitaxel, docetaxel and 10-deacetyl-baccatin III to which galactose or mannose is linked through a spacer, and methods for producing taxoid derivatives comprising reacting paclitaxel, docetaxel or 10-deacetyl-baccatin III with tetrabenzyl acetyloxygalactoside or tetrabenzyl acetyloxymannoside, subjecting the product to debenzylation reaction, and optionally to detriethylsilylation reaction.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: October 23, 2001
    Assignees: Ensuiko Sugar Refining Company, Ltd, Bio Research Corporation of Yokohama, Kaken Pharmaceutical Company, Ltd.
    Inventors: Tadakatsu Mandai, Hiroshi Okumoto, Koji Hara, Katsuhiko Mikuni, Kozo Hara, Yoshinori Tsuchiya, Kosho Nakamura, Teruhiko Umetsu
  • Patent number: 4904470
    Abstract: An antibiotic F-0769 having the following properties:(1) Outer appearance: White or light yellow powder,(2) Melting point: 245.degree.-250.degree. C.,(3) Specific rotation: [.alpha.].sub.D.sup.25 =-37.5.degree. (c=1, methanol),(4) Solubility in solvents: Soluble in methanol, ethanol, acetone, chloroform, ethyl acetate and benzene; and insoluble in water and hexane,(5) Elementary analysis (found %): C:57.53, H:7.36, O:21.17, N:12.97,(6) Ultraviolet absorption spectrum (as measured in methanol: As shown in FIG. 1, .lambda.max(E.sub.1 cm.sup.1%)=213 nm (466), 286 nm (200)(7) Infrared absorption spectrum (as measured by KBr method): As shown in FIG. 2,(8) Nuclear magnetic resonance spectra (as measured in heavy chloroform): .sup.1 H-NMR spectrum is as shown in FIG. 3, and .sup.13 C-NMR spectrum is as shown in FIG. 4,(9) Distinction among basicity, acidity and neutrality: Neutral substance,(10) Amino acid analysis: As a result of the hydrolysis with 6N hydrochloric acid at 110.degree. C.
    Type: Grant
    Filed: March 3, 1987
    Date of Patent: February 27, 1990
    Assignee: Kaken Pharmaceutical Company, Ltd.
    Inventors: Hideo Sugawara, Tomonori Takashina, Nobuko Takahashi, Machiko Sugiyama, Akio Seino, Yukio Miyazaki